UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G					
Under the Securities Exchange Act of 1934					
(Amendment No.)*					
DelMar Pharmaceuticals, Inc.					
(Name of Issuer)					
Common Stock, \$0.001 par value per share					
(Title of Class of Securities)					
<u>247078306</u>					
(CUSIP Number)					
June 3, 2019					
(Date of Event Which Requires Filing of this Statement)					
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:					
a.					
b. ⊠ Rule 13d-1(c) c. □ Rule 13d-1(d)					
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.					
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).					
Page 1 of 8					

CUSIP No.	247078306				
	Names of Reporting Persons. Mitchell P. Kopin				
2. Check the (a) (b)					
3. SEC Use	Only				
4. Citizensh	ip or Place of Organization United S	tates of America			
	5. Sole Voting Power	0			
Number of Shares Beneficially	6. Shared Voting Power	198,244			
Owned by Each Reporting Person With:	7. Sole Dispositive Power	0			
1 013011 17 1111	8. Shared Dispositive Power	198,244			
9. Aggregat	9. Aggregate Amount Beneficially Owned by Each Reporting Person 198,244 (see Item 4)				
10. Check if	he Aggregate Amount in Row (9) Excludes Certain Shares (S	ee Instructions)			
11. Percent o	11. Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)				
12. Type of F IN; HC	Type of Reporting Person (See Instructions) IN; HC				

Page 2 of 8

CUSIP No.	2470783	06			
	Names of Reporting Persons. Daniel B. Asher				
2. Check (a) (b)					
3. SEC U	Use Only				
4. Citize	enship or Place of	Organization United State	es of America		
	5.	Sole Voting Power	0		
Number of Shares Beneficially	y 6.	Shared Voting Power	198,244		
Owned by Each Reporting Person With	7.	Sole Dispositive Power	0		
reison with	8.	Shared Dispositive Power	198,244		
9. Aggre	9. Aggregate Amount Beneficially Owned by Each Reporting Person 198,244 (see Item 4)				
10. Check	k if the Aggregate	Amount in Row (9) Excludes Certain Shares (See	Instructions)		
11. Percen	11. Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)				
	Type of Reporting Person (See Instructions) IN; HC				
		son (See Instructions)			

Page 3 of 8

CUSIP N	o.	24707830	06			
1.	Names of Reporting Persons. Intracoastal Capital LLC					
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b)					
3.	SEC Use Only					
4.	Citizenship or Place of Organization Delaware					
		5.	Sole Voting Power	0		
Ве	Number of Shares Beneficially Owned by Each Reporting Person With:		Shared Voting Power	198,244		
R			Sole Dispositive Power	0		
1 61	ison with.	8.	Shared Dispositive Power	198,244		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 198,244 (see Item 4)					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					
11.	Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)			4.99% (see Item 4)		
12.	Type of Reporting Person (See Instructions) OO					
Page 4 of	8					

Item 1.

(a) Name of Issuer

DelMar Pharmaceuticals, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices

Suite 720-999 West Broadway Vancouver, British Columbia Canada V5Z 1K5

Item 2.

- (a) Name of Person Filing
- (b) Address of Principal Business Office or, if none, Residence
- (c) Citizenship

This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America ("Mr. Kopin"), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

(d) Title of Class of Securities

Common stock, \$0.001 par value per share, of the Issuer (the "Common Stock").

(e) CUSIP Number

247078306

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

(a) and (b):

(i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on June 3, 2019 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 3, 2019), each of the Reporting Persons may have been deemed to have beneficial ownership of 292,500 shares of Common Stock that was to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 9.9% of the Common Stock, based on (1) 2,653,689 shares of Common Stock outstanding as of June 3, 2019 as reported by the Issuer, plus (2) 292,500 shares of Common Stock that were to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes 190,125 shares of Common Stock issuable upon exercise of a warrant that was to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (the "Intracoastal Warrant"), because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 482,625 shares of Common Stock.

(ii) As of the close of business on June 12, 2019, each of the Reporting Persons may have been deemed to have beneficial ownership of 198,244shares of
Common Stock, which consisted of (i) 49,100 shares of Common Stockheld by Intracoastal, and (ii) 149,144 shares of Common Stock issuable upon exercise of the
Intracoastal Warrant, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1)
2,653,689 shares of Common Stock outstanding as of June 3, 2019 as reported by the Issuer, plus (2) 1,170,000 shares of Common Stock in the aggregate issued at the
closing of the transaction contemplated by the SPA, and (3) 149,144 shares of Common Stock issuable upon exercise of the Intracoastal Warrant. The foregoing excludes
40,981 shares of Common Stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant contains a blocker provision under which the holder
thereof does not have the right to exercise the Intracoastal Warrant to the extent that such exercise would result in beneficial ownership by the holder thereof, together
with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock.
Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 239,225 shares of Common Stock.

(c)

Number of sl	hares as to	which	each R	Reporting	Person	has

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: _____198,244 ___.
- (iii) Sole power to dispose or to direct the disposition of _____.
- (iv) Shared power to dispose or to direct the disposition of 198,244

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following b.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Page 6 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 12, 2019

/s/ Mitchell P. Kopin Mitchell P. Kopin

/s/ Daniel B. Asher

Daniel B. Asher

Intracoastal Capital LLC

By: /s/ Mitchell P. Kopin

Mitchell P. Kopin, Manager

Page 7 of 8

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: June 12, 2019

/s/ Mitchell P. Kopin

Mitchell P. Kopin

/s/ Daniel B. Asher

Daniel B. Asher

Intracoastal Capital LLC

By: /s/ Mitchell P. Kopin

Mitchell P. Kopin, Manager

Page 8 of 8